Patients With HCV, Chronic Kidney Disease Less Likely to Receive Antivirals
Individuals with CKD and HCV infection achieve high cure rates with newer anti-HCV treatment regiments.
Investigators of this real-world Italian study found that treatment with protease inhibitors (ie, asunaprevir/simeprevir) should be avoided in patients with advanced liver disease.
Needle and syringe programs are a highly effective, low-cost intervention to reduce HCV transmission.
In adults with chronic HBV infection who have never received treatment, spontaneous loss of hepatitis B surface antigen is infrequent.